Clairet Lipide

Alaves boss sends fierce warning to Barcelona ahead of must-win La Liga clash: ‘We’ll have to give 200%’

· Yahoo Sports

Alaves boss sends fierce warning to Barcelona ahead of must-win La Liga clash: ‘We’ll have to give 200%’

While Barcelona continue to enjoy the mood surrounding another successful league campaign, things look very different for Deportivo Alaves ahead of their upcoming meeting.

Visit extonnews.click for more information.

For Alaves, survival is still the priority, and manager Quique Sanchez Flores knows his side is heading into one of their toughest challenges of the season against a Barcelona team that has set the standard in Spain.

Speaking ahead of the match, the Alaves coach made it clear that his players cannot afford anything less than a perfect performance if they want to compete with the Catalan giants.

“We need to read the game well because we’re up against the best team in the Spanish league. 

“Barcelona will field their strongest side, and we’ll have to give 200% to make this a night to remember.”

Not expecting sympathies from Barcelona

Sanchez Flores does not expect Barcelona to slow down despite already having reasons to celebrate this season. 

In fact, he believes Hansi Flick’s side will approach the match with the same intensity and aggression that has made them one of Europe’s most dangerous teams this year.

Quique Sanchez Flores has not thrown in the towel yet. (Photo by Clive Brunskill/Getty Images)

“We expect that, however they play, they’ll be very good. They’ll stick to their system and be aggressive. 

“They will undoubtedly dominate, and what we have to try to do is hurt them by capitalising on certain strengths that I think might unsettle them.”

There is clear respect from the Alaves camp towards Barcelona, but there is also a belief that they can create problems if they manage the game correctly. 

Sanchez Flores wants his players focused entirely on their own performance rather than getting distracted by Barcelona’s starting XI or attitude heading into the clash.

“The only thing I can think about is what we can do, which is what depends on us. 

“We have to put out of our minds anything that doesn’t depend on us, because all it will do is cloud our focus,” he concluded.

Source: AS

Read full story at source

London prisoner with muscle-wasting condition claims he has to crawl on floor

· The Guardian

Read full story at source

Cipla Q4 Profit Drops 55% To ₹543 Crore As Expenses Weigh On Earnings

· Free Press Journal

Mumbai: Cipla Ltd reported a 55.3 per cent year-on-year decline in consolidated net profit to Rupees 542.5 crore for Q4 FY26, compared with Rupees 1,214.1 crore in the corresponding quarter last year. Revenue from operations for the March quarter stood at Rupees 6,541.2 crore against Rupees 6,729.7 crore a year earlier and Rupees 7,074.5 crore in Q3 FY26, reflecting a sequential slowdown in business momentum.

The pharmaceutical company’s quarterly earnings were impacted by higher operating costs, employee expenses, and impairment charges during the period. Total income declined to Rupees 6,689.4 crore from Rupees 7,019.2 crore in Q4 FY25 and Rupees 7,280.8 crore in the preceding quarter. Meanwhile, total expenses rose to Rupees 5,982.3 crore from Rupees 5,514.9 crore in the year-ago quarter.

Visit freshyourfeel.com for more information.

Cipla Commits $100 Million Investment To Fund InvaGen Operations & Capex Needs

Sequential Performance Moderates In Q4

On a quarter-on-quarter basis, Cipla’s consolidated net profit fell 19.5 per cent from Rupees 674.3 crore reported in Q3 FY26. Revenue from operations also declined 7.5 per cent sequentially. The company recorded an impairment charge of Rupees 42 crore related to associates due to changes in business conditions and market dynamics. Depreciation and amortisation expenses increased to Rupees 382.9 crore during the quarter from Rupees 278.4 crore in Q3 FY26.

Employee benefit expenses rose to Rupees 1,414.3 crore in Q4 FY26 compared with Rupees 1,325 crore in the previous quarter, while other expenses stood at Rupees 1,881.3 crore. Basic earnings per share fell to Rupees 6.87 from Rupees 15.13 in the year-ago quarter and Rupees 8.37 in Q3 FY26.

Pharma Major Cipla Reports 3.7% Rise In Net Profit At ₹1,353.37 Crore For The Second Quarter

Full-Year Revenue Improves, Profit Declines

For the full financial year FY26, Cipla reported consolidated revenue from operations of Rupees 28,162.6 crore, up from Rupees 27,547.6 crore in FY25. However, annual net profit declined to Rupees 3,861.7 crore from Rupees 5,269.2 crore in the previous fiscal. The company attributed part of the pressure on profitability to the implementation impact of India’s new labour codes, which resulted in a one-time liability increase of Rupees 275.9 crore during the year.

Dividend Recommendation And Acquisition Update

The board recommended a final dividend of Rupees 13 per equity share for FY26. During the fiscal year, Cipla completed the acquisition of Inzpera Healthsciences Limited for Rupees 110.7 crore and also approved a scheme for its amalgamation with the company, subject to regulatory approvals.

Disclaimer: This report is based on Cipla’s audited Q4 FY26 financial results and is not investment advice.

Read full story at source